St. Jude Children's Research Hospital, US, scientists created a new combination therapy method to tackle drug resistance in a type of leukaemia with KMT2A gene rearrangement.
List view / Grid view
A mechanism linked to a genetic mutation could help identify patients who are at higher risk of developing leukaemia.
Researchers from the US have identified several new small molecules that can induce mitophagy in leukaemia cells.
A new study has highlighted that the interferon gamma receptor pathway is necessary for CAR T-cell mediated killing in solid tumours.
Researchers have found that the Lamin B1 mutation causes odd-shaped nuclei in blood cancer cells, which may lead to improved care for leukaemia patients.
Using chemical genetic screening and pre-clinical model studies, researchers have discovered that inducing ubiquitin-mediated degradation of mutant EZH2 could provide a more effective treatment strategy for haematologic malignancies.
CRISPR-Cas9 and stem cell technologies have been used to create a cellular model of acute myeloid leukaemia, revealing therapeutic targets.
Researchers have discovered that two enzymes called APOBEC3C and ADAR1 work together to fuel the transition from pre-cancer stem cells to cancer stem cells in leukaemia.
Researchers have developed a novel CAR T-cell therapy for neuroblastoma which uses gating to limit toxicity and T-cell exhaustion.
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
Cancer researchers have created a new class of drugs to selectively target and destroy myeloid leukaemia cells with TET gene mutations.
Researchers have found they can make leukaemia cells vulnerable by dislodging leukaemia stem cells from a tumour-promoting niche.
Researchers have discovered that disrupting the Gdpd3 gene significantly reduced chronic myelogenous leukaemia relapse in mice.
The study evaluating Down syndrome endothelial cells presented novel drug targets for leukaemia and suggested why DS patients may be at greater risk from the cancer.